[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"survival--tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:survival--tumor":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100621354","the-impact-of-two-stage-turnbull-cutait-pull-through-coloanal-anastomosis-on-stoma-free-survival-in-low-rectal-anal-preserving-surgery-100621354",false,"NCT07369531","The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-preserving Surgery","The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-preserving Surgery: A Multicenter Randomized Controlled Trial (FIAS)","FIAS","Inclusion Criteria:\n\n1. Patients with rectal cancer aged 18-75 years confirmed by pathological biopsy as adenocarcinoma;\n2. Preoperative abdominal contrast-enhanced CT and pulmonary CT (or PET-CT) showed no evidence of distant metastasis;\n3. Preoperative rectal MRI evaluation demonstrated that the tumor was located within 5cm below the anal margin, above the intermuscular groove between the internal and external anal sphincters (anal white line) by 1 cm, and without invasion of the external anal sphincter;\n4. For tumors located above the levator ani hiatus, MRI evaluation showed cT1-3, cN0-1, M0, MRF (-); for tumors located below the levator ani hiatus, MRI evaluation showed cT1-2, cN0-1, M0, MRF (-). For patients who received neoadjuvant therapy, tumors above the levator ani hiatus were downstaged to ycT3NxM0 or below, and tumors below the levator ani hiatus were downstaged to ycT2NxM0 or below;\n5. Preoperative BMI \\\u003C 28 kg\u002Fm²\n6. Patients underwent radical laparoscopic\u002Frobot-assisted total mesorectal excision (TME) or transanal total mesorectal excision (TaTME).\n\nExclusion Criteria:\n\n1. Patients diagnosed with concurrent primary malignant tumors in any other organ or multiple distant colorectal cancers;\n2. History of previous open surgery (non-minimally invasive procedures);\n3. Failure to undergo preoperative rectal MRI evaluation and chest\u002Fabdominal imaging assessment, resulting in incomplete clinical staging of the tumor;\n4. Pregnant patients or those with concurrent inflammatory bowel disease;\n5. Preoperative patients with complete intestinal obstruction or requiring emergency surgery;\n6. Preoperative anticipated multivisceral resection or intraoperative required combined organ resection is indicated.;\n7. Recent treatment for other malignancies;\n8. Low rectal cancer classified as type IV in the Bordeaux classification system;\n9. Intraoperatively confirmed distant metastatic disease\n10. Preoperative pathological types of signet ring cell carcinoma, mucinous adenocarcinoma, anaplastic carcinoma, or poorly differentiated carcinoma.\n\nWithdrawal Criteria\n\n1. Patients who refuse surgical intervention after randomization.\n2. Patients who undergo an abdominoperineal resection (APR) following randomization.\n3. Patients who request voluntary withdrawal from the trial at any time throughout the study period.","ALL","18 Years","75 Years",{"count":21,"type":22},520,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to explore the difference in 3-year stoma-free survival between the Turnbull-Cutait delayed coloanal anastomosis (TCA) surgery and the low anterior resection combined with protective stoma (LAR) surgery in patients with low rectal cancer, as well as the differences in anal function, surgical complications, and survival outcomes within 1 year after surgery. The main questions it aims to answer are:\n\n1. Is TCA surgery superior to LAR surgery in improving the 3-year stoma-free survival of patients with low rectal cancer?\n2. Are there differences in postoperative anal function (assessed by LARS score and Wexner score), quality of life (assessed by EORTC QLQ-CR29 questionnaire), surgical complications, pathological outcomes, and long-term survival (disease-free survival, time to recurrence, overall survival) between the two surgical methods? Researchers will compare the TCA group and the LAR group to see if TCA surgery can reduce the permanent stoma rate, improve postoperative anal function and quality of life, and ensure surgical safety and favorable tumor-related outcomes compared with LAR surgery.\n\nParticipants will:\n\n1. Be randomly assigned to either the TCA group or the LAR group in a 1:1 ratio.\n2. Receive the corresponding surgical intervention.\n3. Complete regular follow-ups at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months, and 36 after the first surgery.\n4. Provide relevant clinical data (perioperative, pathological, follow-up) as required.",[28,29,30,31,32],"Rectal Cancer","Surgical Anastomosis","Survival , Tumor","Anal Function","Stoma",[34,35,36,37],"Turnbull-Cutait anastomosis","Rectal neoplasms","Low anterior resection","Stoma-free survival","RECRUITING","2026-03-21",{"date":41,"type":42},"2026-03-25","ACTUAL",{"date":44,"type":42},"2026-03-18",{"date":46,"type":22},"2031-12-31",{"name":48,"class":49},"The First Hospital of Jilin University","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100601877","clinical-research-on-moderately-hypofractionated-adaptive-postoperative-radiotherapy-for-high-risk-endometrial-cancer-100601877","NCT07116213","Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer","Inclusion Criteria:\n\n* Age : 18-70 years old.\n* Performance Status :\n\nECOG score 0-2.\n\n* Expected to comply with oART (Online Adaptive Radiotherapy) workflow.\n* Initial Surgical Treatment :\n\nTotal hysterectomy and bilateral salpingo-oophorectomy ± Pelvic and\u002For para-aortic lymph node dissection\u002Fsampling or sentinel lymph node biopsy.\n\n* Pathological Staging \\& Histology (per FIGO 2009):\n\nStage I :\n\nGrade 3 endometrioid adenocarcinoma with superficial myometrial invasion and extensive LVSI (Lymphovascular Space Invasion).\n\nGrade 2 endometrioid adenocarcinoma with deep myometrial invasion and extensive LVSI.\n\nGrade 3 endometrioid adenocarcinoma with deep myometrial invasion. Stage II-IIIC1 : Endometrioid carcinoma. Stage I-IIIC1 : Serous carcinoma or clear cell carcinoma.\n\n* Informed Consent :\n* Patients and families fully understand the study protocol.\n* Voluntarily participate and sign informed consent forms before enrollment\n\nExclusion Criteria:\n\n* Prior Radiotherapy : History of abdominal or pelvic irradiation.\n* Treatment Interval :\n\nWithout adjuvant chemotherapy: \\>12 weeks between surgery and radiotherapy initiation.\n\nWith adjuvant chemotherapy: \\>6 months between surgery and radiotherapy initiation.\n\n* Malignancy History : Prior diagnosis of other malignancies.\n* Pregnancy\u002FLactation : Pregnant or breastfeeding women.\n* Active Infection : Fever or uncontrolled active infection.\n* Inflammatory Bowel Disease (IBD) : History of IBD (regardless of activity status).\n* Comorbidities : Severe conditions affecting trial compliance, including: Unstable cardiac disease requiring treatment, renal impairment, chronic hepatitis, poorly controlled diabetes, psychiatric disorders","FEMALE","70 Years",{"count":59,"type":22},20,[25],"1. Study Type: Single-center, single-arm, prospective study.\n2. Sample Size: 20 patients with high-risk endometrial cancer were enrolled.\n3. Treatment Procedure:\n\n   The existing clinical oART (Online Adaptive Radiotherapy) workflow protocol for malignant tumors used in our department was applied.\n\n   Procedures included simulation, target volume delineation, radiotherapy planning, and treatment delivery.\n\n   External beam radiation therapy (EBRT) was delivered using moderate hypofractionation.\n\n   If indicated, brachytherapy was performed after the completion of EBRT. When combined with chemotherapy, radiotherapy could be administered during chemotherapy intervals or after completion of chemotherapy.\n4. Study Endpoints:\n\nPrimary Endpoint: Incidence of acute toxicity. Secondary Endpoints: 3-year failure-free survival (FFS) rate, incidence of chronic toxicity, quality of life (QoL), treatment costs, etc.",[63,64,65,66,30],"Endometrial Cancer","Hypofractionated Dose","Radiotherapy, Adjuvant","Side Effects",[68,69,70],"endometrial cancer","Hypofractionated dose","Radiotherapy","2025-08-04",{"date":73,"type":42},"2025-08-11",{"date":75,"type":42},"2025-06-30",{"date":77,"type":22},"2030-12-30",{"name":79,"class":49},"Xiaorong Hou",1]